InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.870

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$415 Starpharma presenting at Bell Potter LifeScience Conference 1 Nov 2012 10:04AM $1.620 $0.870 fallen by 46.30%
$415 Appendix 4C - quarterly 31 Oct 2012 10:00AM $1.625 $0.870 fallen by 46.46%
$415 New formulations show further improvement in crop protection 30 Oct 2012 12:33PM $1.600 $0.870 fallen by 45.63%
$415 Starpharma's docetaxel demonstrates targeted tumour delivery 29 Oct 2012 9:56AM $1.630 $0.870 fallen by 46.63%
$415 VivaGel BV Phase 3 trials - recruitment complete 18 Oct 2012 9:01AM $1.465 $0.870 fallen by 40.61%
$415 Starpharma signs cancer drug agreement with AstraZeneca 6 Sep 2012 9:51AM $1.530 $0.870 fallen by 43.14%
$415 Annual Report and full year financial results 27 Aug 2012 2:09PM $1.490 $0.870 fallen by 41.61%
$415 Starpharma and Nufarm sign crop protection agreement 7 Aug 2012 12:09PM $1.475 $0.870 fallen by 41.02%
$415 Reports rapid advancement of drug delivery program 3 Jul 2012 6:33PM $1.400 $0.870 fallen by 37.86%
$415 Full enrolment achieved for BV Phase 2 & first Phase 3 trial 25 Jun 2012 10:54AM $1.315 $0.870 fallen by 33.84%
$415 Starpharma`s VivaGel Phase 3 trials 60% enrolled 4 Jun 2012 10:13AM $1.370 $0.870 fallen by 36.50%
$415 Appendix 4C - quarterly 30 Apr 2012 10:24AM $1.835 $0.870 fallen by 52.59%
$415 Response to an ASX price query 24 Apr 2012 8:58AM $1.800 $0.870 fallen by 51.67%
$415 SPL Commences pivotal phase 3 VivaGel BV treatment trials 22 Mar 2012 8:26AM $1.600 $0.870 fallen by 45.63%
$415 Half Yearly Report and Accounts 20 Feb 2012 2:21PM $1.430 $0.870 fallen by 39.16%
$415 Appendix 4C - quarterly 30 Jan 2012 10:15AM $1.210 $0.870 fallen by 28.10%
$415 SPL receives FDA Special Protocol Assessment for BV Phase 3 11 Jan 2012 9:15AM $1.210 $0.870 fallen by 28.10%
$415 Starpharma`s drug delivery program with Lilly advances 19 Dec 2011 9:36AM $1.180 $0.870 fallen by 26.27%
$415 Starpharma secures European (EMA) agreement on BV Phase 3 21 Nov 2011 3:08PM $1.150 $0.870 fallen by 24.35%
$415 Starpharma completes A$32 million placement, SPP to follow 16 Nov 2011 9:50AM $1.075 $0.870 fallen by 19.07%
$415 Trading Halt 14 Nov 2011 9:27AM $1.075 $0.870 fallen by 19.07%
$415 Appendix 4C - quarterly 27 Oct 2011 11:44AM $1.120 $0.870 fallen by 22.32%
$415 Starpharma secures FDA agreement on BV treatment Phase 3 10 Oct 2011 9:26AM $0.990 $0.870 fallen by 12.12%
$415 Annual report and full year financial results 29 Aug 2011 1:56PM $1.215 $0.870 fallen by 28.40%
$415 GSK awarded funds for dermal treatment with SPL`s dendrimers 22 Aug 2011 9:31AM $1.025 $0.870 fallen by 15.12%

726 - 750 of 889 results

Page 30 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.